within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01M_QuinoloneAntibacterials.J01MA24_Levonadifloxacin;

model Levonadifloxacin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.9444444444444444e-06,
    adminDuration = 600,
    adminMass = 800 / 1000000,
    adminCount = 1,
    Vd = 0.0148,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0076,
    k12 = 1.0000000000000002e-06,
    k21 = 1.0000000000000002e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Levonadifloxacin</td></tr><tr><td>ATC code:</td><td>J01MA24</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>800</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>14.8</td><td>L</td></tr>
    <tr><td>clearance:</td><td>7.0</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Levonadifloxacin is a broad-spectrum, novel benzoquinolizine fluoroquinolone antibiotic used primarily for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital-acquired pneumonia. It is effective against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). Levonadifloxacin has been approved for clinical use in India.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult subjects following intravenous administration.</p><h4>References</h4><ol><li><p>Bhatia, A, et al., &amp; Friedland, HD (2020). Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study. <i>The Journal of the Association of Physicians of India</i> 68(8) 30–36. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32738837/\">https://pubmed.ncbi.nlm.nih.gov/32738837</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01MA24 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Levonadifloxacin;
